ストックスクリーナーアプリを入手
81.57
0.98%
0.79
アフターアワーズ：
80.73
-0.84
-1.03%
前日終値:
$80.78
開ける：
$81.5
24時間の取引高:
2.03M
Relative Volume:
1.17
時価総額：
$9.68B
収益：
$1.51B
当期純損益:
$348.84M
株価収益率:
29.34
EPS:
2.7805
ネットキャッシュフロー:
$667.65M
1週間 パフォーマンス:
+4.22%
1か月 パフォーマンス:
+14.04%
6か月 パフォーマンス:
+8.60%
1年 パフォーマンス:
+50.44%
1日の値動き範囲:
$80.61
$82.26
1週間の範囲:
$75.71
$82.26
52週間の値動き範囲:
$54.15
$82.26
Halozyme Therapeutics Inc Stock (HALO) Company Profile
名前
Halozyme Therapeutics Inc
セクター
電話
(858) 794-8889
住所
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
81.57 | 9.58B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-04 | ダウングレード | Goldman | Neutral → Sell |
| 2025-10-14 | アップグレード | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-05-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | ダウングレード | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-06-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 開始されました | TD Cowen | Outperform |
| 2023-07-24 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-24 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-10 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Berenberg | Buy |
| 2023-03-16 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 再開されました | Morgan Stanley | Overweight |
| 2022-11-28 | 開始されました | Wells Fargo | Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | 開始されました | Evercore ISI | Outperform |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 繰り返されました | The Benchmark Company | Buy |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | The Benchmark Company | Buy |
| 2020-02-05 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 開始されました | Goldman | Buy |
| 2019-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 再開されました | Piper Jaffray | Neutral |
| 2018-05-11 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 開始されました | Goldman | Neutral |
| 2017-10-16 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-01-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-11-18 | 開始されました | Citigroup | Buy |
| 2015-09-22 | 開始されました | Barclays | Overweight |
| 2015-06-22 | 繰り返されました | JP Morgan | Overweight |
| 2015-03-03 | 繰り返されました | UBS | Buy |
| 2015-02-18 | 繰り返されました | MLV & Co | Buy |
| 2015-01-08 | 繰り返されました | MLV & Co | Buy |
すべてを表示
Halozyme Therapeutics Inc (HALO) 最新ニュース
Halozyme's Q4 earnings miss, higher royalties drive Y/Y revenues - MSN
Halozyme Therapeutics (HALO) Leadership Reset Raises The Question Of Whether The Stock Is Fully Valued - Sahm
Price to sales forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
Halozyme Therapeutics Operating Chief Caudill to Exit - Moomoo
Halozyme stock falls as chief operating officer departs By Investing.com - Investing.com Nigeria
Insider Sell Alert: Bernadette Connaughton Sells Shares of Haloz - GuruFocus
Halozyme stock falls as chief operating officer departs - Investing.com
Halozyme (NASDAQ: HALO) EVP receives new options, RSUs and RSU vesting - Stock Titan
Halozyme (NASDAQ: HALO) CFO awarded large option and RSU package - Stock Titan
Halozyme (HALO) director sells 1,625 shares in 10b5-1 trades - Stock Titan
Halozyme Therapeutics (HALO) COO Cortney Caudill to depart in management reshuffle - Stock Titan
Halozyme Therapeutics, Inc. Announces Departure of Cortney Caudill as Senior Vice President, Chief Operating Officer - marketscreener.com
Is Halozyme (HALO) Elevating Drug Delivery Leadership to Reframe Its Core Investment Narrative? - Sahm
Halozyme names David Ramsay as president drug delivery - Investing.com UK
Halozyme names David Ramsay as president drug delivery By Investing.com - Investing.com South Africa
Halozyme director Mahesh Krishnan sells $547,800 in stock By Investing.com - Investing.com South Africa
Form 4 Halozyme Therapeutics Inc For: 30 June By Investing.com - Investing.com Australia
Halozyme director Mahesh Krishnan sells $547,800 in stock - Investing.com UK
Halozyme (HALO) director exercises options, sells 7,304 shares under plan - Stock Titan
Press Release: Halozyme Appoints David Ramsay as President Drug Delivery - Moomoo
Small Cap Core Portfolio I's Halozyme Therapeutics Inc(HALO) Holding History - GuruFocus
[144] HALOZYME THERAPEUTICS, INC. SEC Filing - Stock Titan
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Price to sales forward of Halozyme Therapeutics, Inc. – FWB:RV7 - TradingView
Price to sales forward of Halozyme Therapeutics, Inc. – BMV:HALO - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (NASDAQ:HALO) - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (DUS:RV7) - TradingView
Halozyme Therapeutics Inc (HALO) Institutional Confidence - TradingKey
Halozyme Therapeutics, Inc. Actuals & Estimates (FWB:RV7) - TradingView
HALO Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
RV7 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
Enterprise value to revenue forward of Halozyme Therapeutics, Inc. – TRADEGATE:RV7 - TradingView
Price to earnings forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection - GlobeNewswire Inc.
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Exploring a 22% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Halozyme Therapeutics Inc (HALO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
META_TITLE_QUOTE - Yahoo Finance
Did Expanding ENHANZE Partnerships and Cash Generation Just Shift Halozyme Therapeutics' (HALO) Investment Narrative? - Sahm
HALOZYME THERAPEUTICS INC (HALO) Stock Chart - ChartMill
Halozyme Therapeutics Inc (HALO) Valuation: PE, PB & Fair Value Analysis - TradingKey
What Halozyme Therapeutics (HALO)'s New ENHANZE Partner Data and Analyst Support Means For Shareholders - Sahm
Halozyme Therapeutics (HALO) Stock Could Be 18.8% Undervalued As Partner Growth Lifts Sentiment - Sahm
Halozyme Therapeutics Inc (HALO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Halozyme Therapeutics Inc (HALO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Halozyme Therapeutics Inc (HALO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Halozyme Therapeutics Inc (HALO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Halozyme Therapeutics Inc (HALO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO) - The Globe and Mail
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $95 - Moomoo
Halozyme Therapeutics Inc (HALO) 財務データ
収益
当期純利益
現金流量
EPS
Halozyme Therapeutics Inc (HALO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Connaughton Bernadette | Director |
Jul 01 '26 |
Sale |
76.71 |
1,625 |
124,651 |
42,044 |
| Krishnan Mahesh | Director |
Jun 29 '26 |
Option Exercise |
38.46 |
7,304 |
280,912 |
21,766 |
| Krishnan Mahesh | Director |
Jun 29 '26 |
Sale |
75.00 |
7,304 |
547,800 |
14,462 |
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):